The use of infliximab in cutaneous sarcoidosis.
Infliximab, a chimeric (humanized mouse) monoclonal antibody which specifically inhibits TNF-alpha, has recently shown efficacy in the treatment of refractory sarcoidosis. The manifestations of sarcoidosis are diverse; however, the long-term effects on the lungs are often the most life-threatening. We describe a patient with sarcoidosis who experienced the complete resolution of her cutaneous disease and stabilization of her pulmonary symptoms after initiation of infliximab.
Meyerle
Jon H
JH
Department of Internal Medicine, Sections of Dermatology and Pulmonary and Critical Care Medicine, Walter Reed Army Medical Center, 4515 Willard Avenue #1018, Chevy Chase, MD 20815, USA. jon.meyerle@verizon.net
Shorr
Andrew
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D017565:Sarcoidosis, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab